All In Biotech

Drug Trial Radar · NCT05887895

To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects

A Trial Comparing the Pharmacodynamics and Pharmacokinetics of HR20014, INS068 and INS062 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

May 23, 2023

Primary completion

Jul 18, 2023

Study completion Jul 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open, six-sequence, three-period crossover phase I clinical trial in healthy subjects to compare the PK/PD and safety profiles of single dose of HR20014, INS068, and INS062. In this study, 12 subjects were randomly assigned to 6 administration sequences in a ratio of 1:1:1:1:1:1, and HR20014, INS068 or INS062 injection were given subcutaneously three times before and after each sequence.

Conditions

  • Diabetes

Interventions

  • INS062 injection、INS068 injection、HR20014 injectionDrug

    INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS068)Time frame: 0 hour to 6 hours after dosing
  2. Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062)Time frame: 6 hours to 24 hours after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The second affiliated hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.